3rd Nov 2005 07:45
Skyepharma PLC03 November 2005 For immediate release 3 November 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY ORINDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN ORNEW ZEALAND NEITHER THIS ANNOUNCEMENT NOR ANY ACCOMPANYING ANNOUNCEMENT IS AN OFFER OFSECURITIES FOR SALE IN THE UNITED STATES. SECURITIES MAY NOT BE OFFERED OR SOLDIN THE UNITED STATES ABSENT REGISTRATION OR AN EXEMPTION FROM REGISTRATION. THESECURITIES TO BE ISSUED PURSUANT TO THE RIGHTS ISSUE HAVE NOT BEEN AND WILL NOTBE REGISTERED UNDER THE US SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANYSTATE OR OTHER JURISDICTION OF THE UNITED STATES. SKYEPHARMA PLC Rights Issue - approximately 83 per cent acceptances SkyePharma PLC (the "Company") today announces that as at 11.00 a.m. on 2November 2005, the latest time and date for acceptance and payment in full forthe New Ordinary Shares under the terms of the 1 for 5 Rights Issue announced on28 September 2005, valid acceptances had been received in respect of 103,915,282New Ordinary Shares, representing approximately 83 per cent of the total NewOrdinary Shares. In accordance with the arrangements set out in Part 2,paragraph 5 of the prospectus relating to the Rights Issue (the "Prospectus"),Credit Suisse First Boston (Europe) Limited will be seeking subscribers thismorning for the remaining 21,712,075 New Ordinary Shares which were not validlytaken up in the Rights Issue. Definitions used in the Prospectus shall have the same meanings when used inthis announcement unless the context otherwise requires. Enquiries: Telephone: SkyePharma 020 7491 1777Michael Ashton (Chief Executive Officer)Donald Nicholson (Finance Director)Peter Laing (Director of Corporate Communications) Credit Suisse First Boston (Europe) Limited 020 7888 8888Paul NichollsAndrew ChristieStephanie Leouzon Buchanan Communications 020 7466 5000Tim AndersonMark CourtRebecca Skye Dietrich THIS ANNOUNCEMENT IS NOT A PROSPECTUS BUT IS AN ADVERTISEMENT FOR THE PURPOSESOF THE PROSPECTUS RULES OF THE FINANCIAL SERVICES AUTHORITY. NO OFFER,INVITATION OR INDUCEMENT TO ACQUIRE SHARES OR OTHER SECURITIES IN THE COMPANY ISBEING MADE BY OR IN CONNECTION WITH THIS ANNOUNCEMENT. ANY OFFER, INDUCEMENT ORANNOUNCEMENT TO ACQUIRE SHARES IN THE COMPANY HAS BEEN MADE SOLELY BY MEANS OFTHE PROSPECTUS, WHICH WAS PUBLISHED BY THE COMPANY ON 12 OCTOBER 2005, AND ANYDECISION TO KEEP, BUY OR SELL SHARES IN THE COMPANY SHOULD BE MADE SOLELY ON THEBASIS OF THE INFORMATION CONTAINED IN SUCH DOCUMENT. This announcement has been issued by the Company and is the sole responsibilityof the Company. It has been approved solely for the purposes of section 21(2)(b)of FSMA by Credit Suisse First Boston (Europe) Limited of One Cabot Square,London, E14 4QJ. Credit Suisse First Boston (Europe) Limited, which is regulated in the UnitedKingdom by the Financial Services Authority, is acting exclusively for theCompany and for no-one else in connection with the Rights Issue and will not beresponsible to anyone other than the Company for providing the protectionsafforded to customers of Credit Suisse First Boston (Europe) Limited or forproviding advice in relation to the Rights Issue, the contents of thisannouncement or any other matter referred to herein. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L